0000000000194067

AUTHOR

Jesús Millán

showing 27 related works from this author

Agricultural transformations and econòmic backwardness. Andalusia, 1850-1935

2002

La via seguida pel món agrari valencià ha conjuminat, com hem tractat de posar en relleu, aspectes de signe, en principi, contradictori si es valoren a partir de models centrats en una única dimensió dels agents socials. Aquesta polivalència es pot resseguir en la inultiplicitat de funcions econòmiques d'alguns d'aquests agents, com s'esdevé amb els rendistes. Pero també cal tenir molt en compte les formes de legitimació de la propietat agrària rendista, que fomentaven un seguit d'aspiracions peculiars entre els llauradors arrendataris. En aquest sentit, la capacitat per absorbir o incloure un conjunt reiterat de tensions sota la hegemonia d'una propietat no discutida representa un dels pro…

Història contemporàniaagrarian exportationsPaís Valencià; agricultura de regadiu; renda de la terra; relacions socials; segles XIX i XXPaís ValenciàAndalusia; agrarian crisis; agrarian exportations; land rent; rural wagesrenda de la terrarelacions socialsland rentagrarian crisisrural wagesagricultura de regadiuAndalusiasegles XIX i XX
researchProduct

Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado gr…

2017

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyPathologyCirrhosisbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseGastroenterologydigestive system diseases03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPharmacology (medical)Liver damageSteatosisSteatohepatitisCardiology and Cardiovascular MedicineLiver cancerbusinessClínica e Investigación en Arteriosclerosis
researchProduct

La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico

2016

Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol -cLDL+cVLDL+c-remmants+Lp(a)- is the real meas…

medicine.medical_specialtyVery low-density lipoproteinHigh risk patientsbusiness.industryCholesterolHypertriglyceridemia030204 cardiovascular system & hematologymedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePostprandialEndocrinologyCardiovascular preventionchemistryInternal medicineNon hdl cholesterolmedicinelipids (amino acids peptides and proteins)Pharmacology (medical)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana

2016

Objectives The aim of the present study was to develop a multidisciplinary consensus based on the Delphi system to establish clinical recommendations for the management of dyslipidaemia when hyperglycaemia is present, and the relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Methods The questionnaire developed by the scientific committee included four blocks of questions about dyslipidaemia in patients with impaired glucose metabolism. The results of the first two blocks are presented here: a) management of dyslipidaemia; b) relevant factors that should be taken into consideration when prescribing and monitoring treatment with s…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industryType 2 Diabetes MellitusDisease030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusmedicinePharmacology (medical)030212 general & internal medicineRisk factorFamily historymedicine.symptomCardiology and Cardiovascular MedicineIntensive care medicinebusinessMass screeningAbdominal obesityClínica e Investigación en Arteriosclerosis
researchProduct

Management of Dyslipidemia in the Metabolic Syndrome

2007

In order to characterize the metabolic syndrome it becomes necessary to establish a number of diagnostic criteria. Because of its impact on cardiovascular morbidity/mortality, considerable attention has been focussed on the dyslipidemia accompanying the metabolic syndrome. The aim of this review is to highlight the fundamental aspects of the pathophysiology, diagnosis, and the treatment of the metabolic syndrome dyslipidemia with recommendations to clinicians. The clinical expression of the metabolic syndrome dyslipidemia is characterized by hypertriglyceridemia and low levels of high-density lipoprotein-cholesterol (HDL-C). In addition, metabolic syndrome dyslipidemia is associated with hi…

medicine.medical_specialtyBioinformaticsClofibric Acidchemistry.chemical_compoundInsulin resistanceInternal medicineHyperlipidemiamedicineHumansPharmacology (medical)DyslipidemiasMetabolic Syndromemedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseEndocrinologyPostprandialchemistrySpainPractice Guidelines as Topiclipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic syndromeCardiology and Cardiovascular MedicineLipid profilebusinessDyslipidemiaAmerican Journal of Cardiovascular Drugs
researchProduct

El reotismo nobiliario en la agricultura valenciana del siglo XIX

2000

RESUMENEl artículo discute los caracteres sociales de la nobleza terrateniente y el papel de la propiedad «rentista» en el desarrollo agrario valenciano del siglo XIX. En la primera parte se estudia la nobleza propietaria a mediados del siglo XIX y se cuestiona la tesis de su continuidad respecto a los antiguos señores feudales. En la segunda se destaca, a través del estudio de un patrimonio de la nobleza sin título, que la gestión era, a la vez, «rentista» y «empresarial», y se intenta explicar la lógica de este comportamiento.

Economics and EconometricsHistoryMiddle classNobilitymedia_common.quotation_subjectPolitical scienceFeudalismEconomic historylanguageVariety (linguistics)Valencianlanguage.human_languagemedia_commonRevista de Historia Económica / Journal of Iberian and Latin American Economic History
researchProduct

Leaseholders in Capitalist Arcadia: Bourgeois Hegemony and Peasant Opportunities in the Valencian Countryside during the Nineteenth Century

2006

Scholars tend to interpret the European peasantry's incorporation into mass politics at the beginning of the twentieth century in terms of two equally extreme situations, citing either the peasantry's support for traditional oligarchies, or its anti-capitalist radicalism. By contrast, this article explores how the confluence between a broad network of peasant families and leased agricultural properties in the Valencian region of Spain helped generate mass support for an anti-liberal (and eventually Francoist) legal system. The authors highlight the uniqueness of the social and productive context of Valencian agriculture during the late 1800s and early 1900s, as well as the tensions that exi…

Political radicalismHistoryHegemony19th centuryGeography Planning and DevelopmentContext (language use)ValencianArcadiaArts and Humanities (miscellaneous)BourgeoisieSociologyValencian regionbiologyMass politicsLandownersAgricultureHistòria contemporània S.XIXbiology.organism_classificationlanguage.human_languagePeasantPeasantryUrban StudiesTenantsPolitical economylanguageClassicsRural History
researchProduct

Decálogo de recomendaciones clínicas en dislipidemia aterogénica

2014

, fue realizado con el fin de promover ydesarrollar un consenso experto mediante la integracionde la mejor evidencia disponible y la experiencia de unamplio panel de profesionales de diferentes especialidadesmedicas. Para ello se empleo el metodo Delphi, una tecnicade consenso profesional mediante encuesta, fiable y delarga tradicion de uso en la investigacion biomedica, quepermite explorar y unificar las opiniones de un grupoprofesional sobre el tema de interes, sin las dificultades einconvenientes inherentes a los metodos de consenso condiscusion presencial

Pharmacology (medical)Cardiology and Cardiovascular MedicineClínica e Investigación en Arteriosclerosis
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

2016

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyCirrhosisDiseaseGastroenterologyLiver diseaseNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansGeneral Environmental Sciencebusiness.industryGeneral EngineeringArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary SciencesSteatosisSteatohepatitisLiver cancerbusinessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento ( I ). Enfermedad del hígado graso no alcohólico…

2017

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyPathologyCirrhosisHigh prevalencebusiness.industryFatty livernutritional and metabolic diseasesArteriosclerosis030204 cardiovascular system & hematologymedicine.diseaseGastroenterologydigestive system diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicine030211 gastroenterology & hepatologyPharmacology (medical)Liver damageSteatosisSteatohepatitisCardiology and Cardiovascular MedicineLiver cancerbusinessClínica e Investigación en Arteriosclerosis
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

COSMIC project : consensus on the objectives of the metabolic syndrome in clinic

2018

Juan Pedro-Botet,1 Juan F Ascaso,2,3 Vivencio Barrios,4,5 Alejandro De la Sierra,6 Javier Escalada,7,8 Jesús Millán,9 Jose M Mostaza,10 Pablo Pérez-Martínez,8,11 Xavier Pintó,8,12 Jordi Salas-Salvadó,8,13 Pedro Valdivielso14 1Lipids and Vascular Risk Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Endocrinology and Nutrition Service, Hospital Clínico, Universitat de Valencia, Valencia, Spain; 3INCLIVA Research Institute, Diabetes and Metabolic Diseases Ciber (Networked Biomedical Research Centres – CIBERDEM), Carlos III, Valencia, Spain; 4Cardiology Service, Hospital Universitario Ramón y Caja…

medicine.medical_specialtydiabetes preventionSpecialties of internal medicineReviewDiseaseType 2 diabetes030204 cardiovascular system & hematologymetabolic syndromeScientific evidence03 medical and health sciences0302 clinical medicineDiabetes mellitusinsulin resistanceInternal MedicinemedicineCor -- Malalties -- Prevenció030212 general & internal medicineObesityRisk factorDiabetes preventionIntensive care medicineAbdominal obesityobesity.Pharmacologybusiness.industrycardiovascular preventionInsulin resistancemedicine.diseaseDiabetis -- PrevencióCardiovascular preventionRC581-951DyslipidemiaHypertensionObesitatHipertensióMetabolic syndromemedicine.symptombusinessDyslipidemia
researchProduct

Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos

2019

Resumen Es indudable la relacion del cLDL y el riesgo cardiovascular, asi como de los beneficios del tratamiento con estatinas. Una vez conseguido el objetivo de cLDL, son notables las evidencias que demuestran la persistencia de un elevado riesgo cardiovascular, concepto denominado riesgo residual. El riesgo residual de origen lipidico se fundamenta en la dislipidemia aterogenica, caracterizada por un aumento de trigliceridos y de las lipoproteinas ricas en trigliceridos, un descenso del cHDL y alteraciones cualitativas de las particulas LDL. Las medidas mas utilizadas para identificar esta dislipidemia se basan en la determinacion de colesterol total, trigliceridos, HDL, colesterol no HDL…

03 medical and health sciences0302 clinical medicinePharmacology (medical)030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicineClínica e Investigación en Arteriosclerosis
researchProduct

Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis

2017

Resumen Documento de posicionamiento y resumen de las recomendaciones recientemente publicadas por el Grupo de Trabajo de Dislipemia Aterogenica de la Sociedad Espanola de Arteriosclerosis y por la Sociedad Europea de Arteriosclerosis.

03 medical and health sciences0302 clinical medicinePharmacology (medical)030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicineClínica e Investigación en Arteriosclerosis
researchProduct

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

2017

Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia of the Spanish Society of Arteriosclerosis and by the European Society of Arteriosclerosis.

medicine.medical_specialtybusiness.industryHypertriglyceridemiaGeneral EngineeringAdvertisingArteriosclerosis030204 cardiovascular system & hematologymedicine.diseaseAtherosclerosisEurope03 medical and health sciences0302 clinical medicineCardiovascular DiseasesRisk FactorsSpainFamily medicinemedicineGeneral Earth and Planetary SciencesHumans030212 general & internal medicinebusinessGeneral Environmental ScienceDyslipidemiasClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Estándares SEA 2019 para el control global del riesgo cardiovascular

2019

One of the main goals of the Spanish Society of Arteriosclerosis is to contribute to a wider and greater knowledge of vascular disease, its prevention and treatment. Cardiovascular diseases are the leading cause of death in our country and also lead to a high degree of disability and health expenditure. Arteriosclerosis is a multifactorial disease, this is why its prevention requires a global approach that takes into account the different risk factors with which it is associated. Thus, this document summarizes the current level of knowledge and integrates recommendations and procedures to be followed for patients with established cardiovascular disease or high vascular risk. Specifically, t…

Estimationmedicine.medical_specialtyVascular diseasebusiness.industryCardiovascular risk factorsNiceArteriosclerosisDisease030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinemedicinePharmacology (medical)030212 general & internal medicineCardiology and Cardiovascular MedicineIntensive care medicinebusinesscomputerRisk managementCause of deathcomputer.programming_languageClínica e Investigación en Arteriosclerosis
researchProduct

José María Alcalde Jiménez: El poder del señorío. Señorío y poderes locales en Soria entre el Antiguo Régimen y el Liberalismo, Valladolid, Junta de …

1999

Economics and EconometricsHistoryRevista de Historia Económica / Journal of Iberian and Latin American Economic History
researchProduct

Los fibratos en la prevención primaria de la enfermedad cardiovascular. Comentarios a los resultados de una revisión sistemática de la Colaboración C…

2018

Resumen Los fibratos son un grupo de hipolipidemiantes que reducen los trigliceridos, elevan las lipoproteinas de alta densidad y disminuyen la fraccion de particulas de LDL pequenas y densas. Recientemente, se han publicado los resultados de un estudio de la Colaboracion Cochrane sobre su eficacia y seguridad en la prevencion primaria de la enfermedad cardiovascular. Este estudio incluye una revision sistematica y un metaanalisis de 6 estudios (16.135 pacientes) que evaluan, en personas en prevencion primaria, los beneficios clinicos de los fibratos comparados con el uso de un placebo o de otros hipolipidemiantes. Concluyen que, comparados con placebo, los fibratos son utiles para reducir …

03 medical and health sciences0302 clinical medicinePharmacology (medical)030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicineClínica e Investigación en Arteriosclerosis
researchProduct

Colesterol-no HDL como objetivo terapéutico

2019

Although cholesterol linked to low-density lipoproteins (c-LDL) is well established as a risk factor for cardiovascular disease, there is often a more complex dyslipidaemia pattern that contributes to the formation of atherosclerotic plaque. Non-HDL cholesterol (c-NO-HDL) is used to estimate the total amount of atherogenic lipoproteins in plasma, some of which are not usually determined in daily clinical practice. c-NO-HDL is easily calculated from the subtraction of total plasma cholesterol from the cholesterol content carried by high density lipoproteins. The c-NO-HDL has a predictive value superior to that of C-LDL to estimate the risk of major cardiovascular events in epidemiological st…

medicine.medical_specialtyDisease030204 cardiovascular system & hematologyArteriosclerotic heart diseaselaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineEpidemiologyMedicinePharmacology (medical)030212 general & internal medicineRisk factorbusiness.industryCholesterolIncidence (epidemiology)medicine.diseaseClinical trialchemistryCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association wi…

2016

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyCirrhosisDisease030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseMedicineHumansGeneral Environmental Sciencebusiness.industryFatty liverGeneral Engineeringnutritional and metabolic diseasesArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary Sciences030211 gastroenterology & hepatologySteatohepatitisSteatosisbusinessLiver cancerClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Enfermedad renal crónica y dislipidemia

2017

Resumen La enfermedad renal cronica (ERC) ha de ser considerada como una situacion de alto e incluso muy alto riesgo cardiovascular, ya que provoca un aumento de la mortalidad cardiovascular que va incrementandose a medida que progresa la enfermedad. Es preciso realizar un diagnostico precoz de la ERC junto con la adecuada identificacion de los factores de riesgo, al objeto de frenar su evolucion a estadios mas severos, evitar las complicaciones y retrasar, en lo posible, la necesidad de tratamiento sustitutivo renal. La dislipidemia es un factor de progresion de la ERC que aumenta el riesgo de desarrollo de aterosclerosis y sus complicaciones. Su adecuado control contribuye a reducir la el…

03 medical and health sciences0302 clinical medicinePharmacology (medical)030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicineClínica e Investigación en Arteriosclerosis
researchProduct

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

2018

Abstract Fibrates are drugs that reduce triglycerides, elevate high-density lipoproteins, as well as decrease small, dense LDL particles. The results of a study have recently been published by the Cochrane Collaboration on fibrates efficacy and safety in the primary prevention of cardiovascular disease. This study includes a systematic review and a meta-analysis of 6 studies (16,135 patients) that evaluated the clinical benefits of fibrates compared to placebo use or other lipid-lowering drugs. This review showed evidence of a protective effect of the fibrates compared with placebo as regards a reduction 16% of a compound objective of death due to cardiovascular disease, non-fatal myocardia…

medicine.medical_specialtyDiseasePlacebochemistry.chemical_compoundInternal medicinePrimary preventionmedicineHumansMyocardial infarctionHypolipidemic AgentsGeneral Environmental ScienceCreatinineCochrane collaborationbusiness.industryFibric AcidsGeneral EngineeringDiabetic retinopathymedicine.diseaseLipidsPrimary PreventionTotal mortalitychemistryCardiovascular DiseasesCreatinineGeneral Earth and Planetary SciencesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Dislipidemia aterogénica 2019. Documento de consenso del Grupo de Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis

2020

business.industryMedicinePharmacology (medical)Cardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

2019

Abstract There is no doubt about the relationship between LDL-C and cardiovascular risk, as well as about the benefits of statin treatment. Once the objective of LDL-C has been achieved, the evidences that demonstrate the persistence of a high cardiovascular risk, a concept called residual risk, are notable. The residual risk of lipid origin is based on atherogenic dyslipidemia, characterised by an increase in triglycerides and triglyceride-rich lipoproteins, a decrease in HDL-C and qualitative alterations in LDL particles. The most commonly used measures to identify this dyslipidemia are based on the determination of total cholesterol, triglycerides, HDL, non-HDL cholesterol and remaining …

medicine.medical_specialtyApolipoprotein BPhysical exercisechemistry.chemical_compoundFenofibrateRisk FactorsWeight lossInternal medicinemedicineHumansTriglyceridesDyslipidemiasHypolipidemic AgentsGeneral Environmental ScienceFenofibratebiologybusiness.industryCholesterolGeneral Engineeringnutritional and metabolic diseasesAtherosclerosismedicine.diseaseLipidsResidual riskCholesterolEndocrinologychemistryCardiovascular Diseasesbiology.proteinGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessDyslipidemiamedicine.drugLipoproteinClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

2019

In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein chol…

medicine.medical_specialtyendocrine system diseaseschemistry.chemical_compoundTriglycerides/HDL CholesterolInternal medicineMedicineHumanscardiovascular diseasesTriglyceridesGeneral Environmental ScienceLipoprotein cholesterolDyslipidemiasbusiness.industryCholesterolCholesterol HDLGeneral Engineeringnutritional and metabolic diseasesAtherosclerosisEuropechemistryPractice Guidelines as TopicCardiologyEuropean atherosclerosis societyGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)businessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

2020

medicine.medical_specialtybusiness.industryInternal medicineGeneral EngineeringmedicineMEDLINEGeneral Earth and Planetary SciencesArteriosclerosismedicine.diseasebusinessGeneral Environmental ScienceClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

El rentismo nobiliario en la agricultura valenciana en el siglo XIX

2000

Editada en la Fundación Empresa Pública El articulo discute los caracteres sociales de la nobleza terrateniente y el papel de la propiedad «rentista» en el desarrollo agrario valenciano del siglo XIX. En la primera parte se estudia la nobleza propietaria a mediados del siglo XIX y se cuestiona la tesis de su continuidad respecto a los antiguos señores feudales. En la segunda se destaca, a través del estudio de un patrimonio de la nobleza sin título, que la gestión era, a la vez, «rentista» y «empresarial », y se intenta explicar la lógica de este comportamiento. This article aims to discuss the social features of the landed nobility and the role of «rentier» landownership in the development…

N33Nobleza terratenienteN23N53RentistaNobleza terrateniente ; Rentista ; Agricultura ValencianaUNESCO::CIENCIAS ECONÓMICASN93:CIENCIAS ECONÓMICAS [UNESCO]HistoriaEconomíaAgricultura Valenciana
researchProduct